FDA names former pharmaceutical company executive to oversee US drug program
FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency's Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs.
His appointment comes a month after the center's acting director, Dr. Jacqueline Corrigan-Curay, announced her retirement.
As the agency's top drug regulator, Tidmarsh will be charged with following through on a number of commitments made by Makary and his boss, Health Secretary Robert F. Kennedy Jr., including reviewing the safety of the abortion pill mifepristone. The FDA is also scrutinizing certain uses of other long-established drugs, including antidepressants and hormone-replacement drugs for menopause.
Tidmarsh founded and led several pharmaceutical companies, including Horizon Pharmaceuticals, maker of an anti-inflammatory medication for arthritis. He has also served as an adjunct professor at Stanford University.
The FDA's drug center is the agency's largest unit, with nearly 6,000 staffers responsible for reviewing the safety and effectiveness of new drugs and monitoring the use and marketing of older drugs.
About 2,000 FDA staffers have been laid off as part of widescale cuts to the federal health workforce overseen by Kennedy. More than 1,000 others have taken buyouts or early retirement, while many others are reportedly searching for new jobs. The departures have threatened basic FDA operations, including the timely review of new drugs.
Nearly all of the FDA's senior leadership positions have turned over in recent months, either due to retirements, resignations or actions by administration officials placing them on administrative leave.
FDA center directors typically hold their positions for years or even decades, serving across multiple administrations, whether Republican or Democrat.
In May, Makary named Dr. Vinay Prasad, a prominent critic of the FDA's COVID response, to run the agency's vaccine center. He was also named to the post of FDA chief medical officer. Prasad joined the agency after his predecessor, longtime vaccine chief Dr. Peter Marks, was forced out in March.
The head of FDA's tobacco center was also forced to step down in April. A permanent replacement has not yet been named.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
4 hours ago
- Hamilton Spectator
Uruguay confronts a powerful new threat to its palm trees: A tiny red bug
MONTEVIDEO, Uruguay (AP) — Palm trees in Uruguay are more than just plants, they are icons, much like olive groves for Greeks or cherry blossoms for the Japanese. The treasured trees lining one of the world's longest sidewalks through Montevideo, Uruguay's capital, and adorn the swanky Atlantic beach resorts of Punta del Este have recently come under ruthless attack. Across the small South American country, palm trees are falling prey to a fierce enemy measuring just 5 centimetres (2 inches) in length: The red palm weevil. First the elegant fronds droop. Then the tell-tale holes appear in the trunk. Soon enough, the tree is tilting toward collapse. The weevil has devoured thousands of Uruguay's palm trees since its unexplained arrival from Southeast Asia in 2022. But authorities are only now waking up to the threat as the landscape of municipalities transforms and fears grow that the country's beloved palms could be wiped out. 'We are late in addressing this,' Estela Delgado, the national director of biodiversity at Uruguay's Ministry of Environment, acknowledged last month. 'But we are doing so with great commitment and seriousness.' The insect and its devastating impact can be found in 60 countries around the world but nowhere else in South America . Authorities first detected it in the town of Canelones, bordering Montevideo, where the insect killed more than 2,000 palm trees in less than a month. Weevils quietly wreak destruction by boring through the open scars of pruned palms and laying hundreds of eggs inside. When larvae hatch, they tunnel through trunks and eat up the trees' internal tissue. Death strikes within weeks. The Uruguayan government set up a task force to combat the plague in March. In May, Environment Minister Edgardo Ortuño declared the fight against the red palm weevil 'a national priority.' As of this year, the red bug has proliferated in eight of the country's 19 regions, including Montevideo. Half of the capital's 19,000 palm trees have been infected, estimates Gerardo Grinvald, director of pest control company Equitec, which helps authorities combat the bug. The insect first attacks decorative Canary palms, the tree in so many pictures of Uruguay's sunny landscape, before moving onto its date palms. 'It's an invisible pest,' Grinvald said, explaining the challenge of identifying an infestation when it starts. As a result, landowners fail to isolate and quarantine their trees, fueling the weevil's crawl across the country. The Montevideo municipality this year earmarked $70,000 for chemical pesticide sprays and insecticide injections meant to kill bugs inside infested trunks, with the goal of saving some 850 trees in the city's prominent Parque Rodó, a scenic urban park along the coast. In the southeast corner of Uruguay, home to Punta del Este, a beachy, palm-fringed haven for jet-set elites from all over the world, authorities recently allocated $625,000 for efforts to dispose of infected trees and lure weevils away from affected areas with pheromone traps and other methods. 'We are losing our palm trees,' lamented Montevideo resident Rafael dos Santos as he walked his dog in Parque Rodó. 'They are historic in Uruguay, and a part of us.' As the weevil's march continues unabated, authorities now fear native trees of Uruguay's UNESCO biosphere reserve bordering Brazil will fall victim next, potentially facilitating the spread of the parasite across an unprepared continent. ___ Follow AP's coverage of Latin America and the Caribbean at .
Medscape
4 hours ago
- Medscape
FDA Declines to Approve New Melanoma Therapy
The FDA has declined to approve a new oncolytic immunotherapy, vusolimogene oderparepvec (RP1), to treat advanced melanoma. The agency recently issued a complete response letter to the company, Replimune Group, rejecting its biologics license application that sought approval for the new agent in combination with nivolumab (Opdivo) to treat adults with advanced melanoma. In the complete response letter, the FDA indicated that it can't approve the biologics license application for vusolimogene oderparepvec because the company's IGNYTE trial 'is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness,' Replimune explained in a press release. According to Replimune, the complete response letter also noted that the trial data 'cannot be adequately interpreted due to the heterogeneity of the patient population,' and that 'there are items related to the confirmatory trial study design which need to be addressed.' 'We are surprised by the FDA decision and disappointed for advanced melanoma patients who have limited treatment options, as highlighted by the granting of breakthrough status at the time we provided the IGNYTE primary data,' stated Sushil Patel, PhD, Replimune's chief executive officer. Vusolimogene oderparepvec is the lead product candidate for the biotech company. Patel further noted that the issues raised in the complete response letter were not 'raised by the agency in mid- and late-cycle reviews.' Additionally, he said, 'we had also aligned on the design of the confirmatory study.' The FDA's response to the biologics license application for the new agent, along with its recently announced policy requiring randomized, controlled trials for approval of COVID vaccines in healthy Americans younger than 65 years, may signal that the agency is taking a tougher stance on new drug approvals. Replimune plans to 'urgently interact with the FDA to find a path forward for the timely accelerated approval of RP1,' according to its statement. Sharon Worcester, MA, is an award-winning medical journalist based in Birmingham, Alabama, writing for Medscape Medical News, MDedge, and other affiliate sites. She currently covers oncology, but she has also written on a variety of other medical specialties and healthcare topics. She can be reached at sworcester@ or on X @SW_MedReporter.
Time Business News
5 hours ago
- Time Business News
Next-Gen Mental Health Apps
A mental health app is a digital tool designed to support emotional welfare, stress, anxiety, depression, or other mental health conditions through mood tracking, directed therapy, attention, cognitive behavior technique and characteristics such as AI-operated chat support. Mental health app growth of market growth is inspired by increasing mental health awareness, increasing smartphone penetration, increasing demand for accessible and inexpensive mental health solutions and lack of mental health professionals. Additionally, the Covid-19 epidemics accelerated the adoption of digital health equipment, while innovations in AI, privatization and data analytics continue to promote user's busyness and market expansion. Key Growth Drivers and Opportunities Increasing Mental Health Awareness: Mental health awareness is a major driver of the mental health app market, as it encourages more people to seek help, reduce stigma and prioritize emotional welfare. Since individuals are informed more about the importance of mental health issues and early intervention, demand for mobile apps such as accessible, inexpensive and stigma-free solutions increases rapidly. These apps provide private, on-demand support for stress, anxiety, depression and self-care, which they appeal to broad audiences-especially in areas with limited access to traditional mental health services. This growing awareness fuel the user and fuel investment in new digital mental health equipment. Challenges The mental health app market has constraints such as the issue of data privacy and security amid the storing and processing of sensitive personal information. The fact-evidence is that most of these applications have never undergone clinical trials and, as a result, it is clearly not guaranteed that they will work for everyone, hence the question of their efficiency and safety. The reason behind this is that there is no proper authority for monitoring the activities of these platforms leading to quality disparities. As if that is not enough, there are social barriers such as the limited number of people who own smartphones, those without digital literacy, or people without a stable internet connection that hinder many others from accessing the apps. Innovation and Expansion Supportive Mind' App for Mental Wellness Launched by Infosys and Mental Health Foundation Australia In June 2025, the 'Supportive Mind' mobile app is the result of a strategic partnership between Infosys, a worldwide leader in next-generation digital services and consultancy, and Mental Health Foundation Australia (MHFA) to raise awareness of mental health issues. The goal of this Infosys-developed app for MHFA is to give communities and first responders in Australia and New Zealand instant access to mental health services. This program is a component of Infosys' commitment to corporate social responsibility, which aims to use technology to promote the welfare of communities. The application aims to provide practical answers for proactive self-care and assistance by filling in knowledge gaps on mental health. Magellan Health Releases Youth Support App for Mental Wellness In September 2024, in The Teen Mental Wellbeing app was released by Magellan Health, Inc., a pioneer in behavioral health and associated services, to promote the mental and emotional health of adolescents and young adults (ages 13 to 22). Through evidence-based practices and digital tools supported by research, the app promotes the road to mental wellbeing, fosters self-awareness, and increases resilience. It is powered by BeMe Health's cutting-edge digital health platform. With evidence-based tools and real-time human connection, the Teen Mental wellness app, powered by BeMe, is made to meet adolescents and young adults where they are on their phones in a fun and secure setting so they can take proactive measures to manage their wellness. Additionally, the app includes a number of scientifically recognized assessments, such as those for anxiety and depression, which can direct users to the best therapies for them. Inventive Sparks, Expanding Markets The key players operating the mental health app market includes, Addicaid, Silver Cloud Health Inc., Headspace Inc., Aurora health care, Happify Inc., 7 cups of tea, Mood Mission Pvt Ltd., Ustwo Fampany ltd., NOCD Inc., Talkspace, Sanvello Health Inc., Inc., Mindscape, Flow and Youper Inc., Recovery Record Inc., and others. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
